Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients

MA Chen-chen; ZHAI Xiao-hu; QIN Li-yan; GU Jia-yi; MAO Ying; ZULI YA&#183;Shata-er; XIANG Yang

doi:10.16462/j.cnki.zhjbkz.2016.01.005

Volume 20 Issue 1

Jan. 2016

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2016 > 20(1): 17-20

MA Chen-chen, ZHAI Xiao-hu, QIN Li-yan, GU Jia-yi, MAO Ying, ZULI YA·Shata-er, XIANG Yang. Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(1): 17-20. doi: 10.16462/j.cnki.zhjbkz.2016.01.005

Citation:

MA Chen-chen, ZHAI Xiao-hu, QIN Li-yan, GU Jia-yi, MAO Ying, ZULI YA·Shata-er, XIANG Yang. Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(1): 17-20. doi: 10.16462/j.cnki.zhjbkz.2016.01.005

Citation:

MA Chen-chen, ZHAI Xiao-hu, QIN Li-yan, GU Jia-yi, MAO Ying, ZULI YA·Shata-er, XIANG Yang. Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(1): 17-20. doi: 10.16462/j.cnki.zhjbkz.2016.01.005

PDF( 1045 KB)

Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients

doi: 10.16462/j.cnki.zhjbkz.2016.01.005

1. Department of Epidemiology and Health Statistics, Xinjiang Medical University, Urumqi 830011, China;
2. Department of Planned Immunization, Xinjiang Uygur Autonomous Region's Center for Disease Control and Prevention, Urumqi 830011, China

Received Date: 2015-10-17
Rev Recd Date: 2015-11-20

Abstract

Abstract

Objective To investigate the incidence of liver injury in Uygur patients with pulmonary tuberculosis during anti-tuberculosis chemotherapy and explore the causes of possible risk factors of liver injury, for a basis for treatment and control of tuberculosis. Methods A nested case-control study of 1 135 cases of Uygur patients were followed up and data were collected. Potential factors of ATLI were analyzed. Results Incidence of ATLI was 3.08%. The single test showed a history of liver disease was statistically significant (χ²=21.273,P<0.001). The results of multivariate Logistic regression analysis indicated that ATLI was associated with a elevated serum transaminases before treatment (OR=2.978, 95% CI:1.168-7.593) and previous history of hepatitis (OR=21.852,95% CI:5.410-88.196). Conclusions The treatment of TB patients have a elevated serum transaminases before treatment and previous history of hepatitis may be the risk factor of ATLI. In the tuberculosis patients receiving anti-TB drugs, the monitoring of liver function should be strenthened. Patients with possible risk factors should be observed closely so that appropriate measures can be taken to improve the treatment effect.
- Antituberculosis agents,
- Liver,
- Risk factors

FullText(HTML)

References(15)

References

Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China national free antiretroviral treatment program [J]. AnnIntern Med, 2009,151(4):241-251.

Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:comparison between low-come and high-income countries [J]. Lancet, 2006,367(9513):817-824.

张福杰. 国家免费艾滋病抗病毒治疗手册 [M]. 第3版. 北京:人民卫生出社, 2012:15-18.

彭国平,李旺华,占发先,等. 湖北省2715例接受艾滋病免费抗病毒治疗者生存分析 [J]. 公共卫生与预防医学, 2011,22(5):33-36.

姚世堂,段松,项丽芬,等. 云南省德宏州3103例艾滋病患者抗病毒治疗后生存分析 [J]. 中华流行病学杂志, 2010,11(31):1215-1218.

Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy [J]. Ann Intern Med, 2000,133(6):401-410.

Cuong do D, Thorson A, Sonnerborg A, et al. Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam [J]. Scand J Infect Dis, 2012,44(3):201-208.

杨红,陈果,周良君,等. 绵阳市228例艾滋病感染者和病人CD4⁺T淋巴细胞检测分析 [J]. 中国热带医学, 2013,13(3):335-342.

原琛利,穆生财,薛子东. 山西省艾滋病抗病毒治疗死亡病例流行病学分析 [J]. 中华疾病控制杂志, 2014,18(12):1184-1186.

周琳,吴琼海,沈伟伟,等. 浙江台州市接受抗病毒治疗的艾滋病患者生存分析 [J]. 中华疾病控制杂志, 2013,17(12):1049-1051.

兰青. 人类免疫缺陷病毒/艾滋病合并乙型肝炎病毒感染的研究 [D]. 昆明:昆明医学院, 2011.

王昊鹏,杨静静,邓小昭,等. 中国大陆吸毒人群HIV、HBV、HCV感染状况及相关因素的Meta分析 [J]. 中华疾病控制杂志, 2010,14(4):300-304.

杨成彬,古贤德,罗雪文,等. 静脉吸毒艾滋病患者102例抗病毒治疗的疗效分析 [J]. 中国全科医学, 2010,13(28):3188-3190.

Alencar WK, Duarte PS, Waldman EA, et al. Survival analysis of acquired immune deficiency syndromepatients with and without hepatitis C virus infection at areference center for sexually transmitted diseases/acquiredimmune deficiency syndrome in Sao Paulo,Brazil [J]. Braz J Infect Dis, 2014,18(2):150-157.

孙定勇,王奇,杨文杰,等. 河南省2003-2009年艾滋病抗病毒治疗患者生存情况分析 [J]. 中华流行病学杂志, 2012,33(2):181-184.

Relative Articles

Supplements(0)

Cited By

Proportional views